# Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

> **NCT04321031** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 256 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis With Liver Fibrosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06865571
- **DRUG:** PF-05221304

## Key facts

- **NCT ID:** NCT04321031
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2024-01-23
- **Final completion:** 2024-02-21
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04321031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04321031, "Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04321031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*